IN2014CN04823A - - Google Patents

Info

Publication number
IN2014CN04823A
IN2014CN04823A IN4823CHN2014A IN2014CN04823A IN 2014CN04823 A IN2014CN04823 A IN 2014CN04823A IN 4823CHN2014 A IN4823CHN2014 A IN 4823CHN2014A IN 2014CN04823 A IN2014CN04823 A IN 2014CN04823A
Authority
IN
India
Prior art keywords
rsv
hybridoma
secreted
relates
monoclonal antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Parra Alexis Mikes Kalergis
Ramirez Susan Marcela Bueno
Alarcon Jorge Eugenio Mora
Johnson Roberto Sebastián Gómez
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Publication of IN2014CN04823A publication Critical patent/IN2014CN04823A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/115Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4823CHN2014 2011-11-25 2012-11-23 IN2014CN04823A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2011003002A CL2011003002A1 (es) 2011-11-25 2011-11-25 Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
PCT/IB2012/056688 WO2013076702A2 (es) 2011-11-25 2012-11-23 Anticuerpos monoclonales específicos para el antígeno m2-1 del virus respiratorio sincicial (vrs)

Publications (1)

Publication Number Publication Date
IN2014CN04823A true IN2014CN04823A (enrdf_load_stackoverflow) 2015-09-18

Family

ID=51205767

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4823CHN2014 IN2014CN04823A (enrdf_load_stackoverflow) 2011-11-25 2012-11-23

Country Status (13)

Country Link
US (1) US9273122B2 (enrdf_load_stackoverflow)
EP (1) EP2784088B1 (enrdf_load_stackoverflow)
CN (1) CN103998465B (enrdf_load_stackoverflow)
AR (1) AR088987A1 (enrdf_load_stackoverflow)
CA (1) CA2856258C (enrdf_load_stackoverflow)
CL (1) CL2011003002A1 (enrdf_load_stackoverflow)
ES (1) ES2657619T3 (enrdf_load_stackoverflow)
IN (1) IN2014CN04823A (enrdf_load_stackoverflow)
MX (1) MX349235B (enrdf_load_stackoverflow)
PE (1) PE20141683A1 (enrdf_load_stackoverflow)
PT (1) PT2784088T (enrdf_load_stackoverflow)
WO (1) WO2013076702A2 (enrdf_load_stackoverflow)
ZA (1) ZA201403564B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2014003373A1 (es) * 2014-12-11 2015-04-10 Univ Pontificia Catolica Chile Anticuerpos monoclonales especificos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares , útiles para la deteccion y el diagnostico de la infeccion causada por hmpv.
JP6270781B2 (ja) * 2015-06-30 2018-01-31 田中貴金属工業株式会社 クロマト分析装置およびクロマト分析方法
CL2015002152A1 (es) 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3848389A4 (en) * 2018-09-03 2022-04-13 Pontificia Universidad Católica De Chile SPECIFIC MONOCLONAL ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) N-ANTIGEN FOR TREATMENT, DETECTION AND DIAGNOSIS OF INFECTION
RU2713340C1 (ru) * 2018-12-28 2020-02-04 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам респираторно-синцитиального вируса
CN115838419B (zh) * 2022-09-27 2023-06-30 深圳重链生物科技有限公司 抗呼吸道合胞病毒抗体及其相关应用
WO2024120516A1 (zh) * 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762905A (en) * 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
AU689489B2 (en) 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
AU3005500A (en) * 1999-02-26 2000-09-14 Uab Research Foundation, The Methods of screening for antiviral compounds
US20020068066A1 (en) 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
CA2463678A1 (en) 2000-10-17 2002-04-25 Besst-Test Aps Assay for directly detecting a rs virus related biological cell in a body fluid sample
US20050176130A1 (en) * 2002-09-27 2005-08-11 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
CN101130765B (zh) 2006-08-21 2011-04-06 北京阿斯可来生物工程有限公司 呼吸道合胞病毒检测试剂盒
KR100938998B1 (ko) * 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체

Also Published As

Publication number Publication date
EP2784088A2 (en) 2014-10-01
CN103998465A (zh) 2014-08-20
WO2013076702A2 (es) 2013-05-30
WO2013076702A3 (es) 2013-07-25
PE20141683A1 (es) 2014-11-28
ES2657619T3 (es) 2018-03-06
PT2784088T (pt) 2018-01-31
MX349235B (es) 2017-07-19
CA2856258A1 (en) 2013-05-30
US20140348858A1 (en) 2014-11-27
MX2014006248A (es) 2015-03-03
EP2784088B1 (en) 2017-10-25
ZA201403564B (en) 2015-08-26
AR088987A1 (es) 2014-07-23
EP2784088A4 (en) 2015-05-13
US9273122B2 (en) 2016-03-01
CA2856258C (en) 2018-05-01
CN103998465B (zh) 2017-02-22
BR112014012608A2 (pt) 2020-10-27
CL2011003002A1 (es) 2012-05-25

Similar Documents

Publication Publication Date Title
IN2014CN04823A (enrdf_load_stackoverflow)
Eisenberg et al. Rituximab-treated patients have a poor response to influenza vaccination
Perricone et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases
Li et al. Characterization of SARS-CoV-2-Specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting
Glenn et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
US10125188B2 (en) Human antibodies to respiratory syncytial virus F protein and methods of use thereof
Wørzner et al. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
US9107906B1 (en) Compositions and methods for the treatment of immunodeficiency
Grasse et al. Booster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adults
Valentini et al. Generation of switched memory B cells in response to vaccination in Down syndrome children and their siblings
Caidi et al. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
Zhao et al. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model
Bergeron et al. Respiratory syncytial virus (RSV) G protein vaccines with central conserved domain mutations induce CX3C-CX3CR1 blocking antibodies
Tabata et al. Neutralizing monoclonal antibodies reduce human cytomegalovirus infection and spread in developing placentas
Su et al. RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses
Hong et al. Antibody-secreting cells with a phenotype of Ki-67low, CD138high, CD31high, and CD38high secrete nonspecific IgM during primary hepatitis A virus infection
CA3173861A1 (en) Natural antibodies in prophylaxis and therapy
Moazen et al. Single chain antibodies against gp55 of Human Cytomegalovirus (HCMV) for prophylaxis and treatment of HCMV infections
Changrob et al. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
Launay et al. Factors associated with humoral immune response to pandemic A/H1N1 (v) 2009 influenza vaccine in cystic fibrosis
WO2013035345A3 (en) Dengue-virus serotype neutralizing antibodies
WO2017084518A1 (zh) 一种疫苗佐剂以及包含该佐剂的疫苗
Rinaldi et al. B-sides serologic markers of immunogenicity in kidney transplanted patients: report from 2012–2013 flu vaccination experience
BR112020025504A2 (pt) Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido